Scholarlink

<p><b>Objectives</b>. To study the efficacy of ampakines (Ampasse) in patients with anxiety and depressive disorders in the early recovery period of ischemic stroke (IS). <b>Materials and methods.</b> The study included 203 patients in the early recovery period of IS, who underwent rehabilitation measures at the Doctor clinic (Tuymazy) from January 2023 to August 2025. The study included patients with IS occurring no later than three months before the start of the study, with signs of anxiety and depression not exceeding 10 points on the Hospital Anxiety and Depression Scale (HADS). Patients of the study group (SG, <i>n</i> = 102, age 63.2 ± 8.9 years, 48 women and 54 men) received Ampasse for 15 days along with standard therapy. Patients in the reference group (RG, <i>n</i> = 101, age 66.3 ± 8.1 years, 45 women and 56 men) received only basal therapy. The Beck Anxiety Inventory, Beck Depression Inventory, HADS, and Spielberger–Hanin Anxiety Inventory were used to assess psychoemotional state. <b>Results</b>. Improvements on all psychometric scales in the SG was statistically significantly greater than those in the RG. <b>Conclusions</b>. The study results showed that Ampasse had positive effects in terms of reducing the symptoms of anxiety and depression in patients in the early recovery period of ischemic stroke.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mixed Anxious-Depressive Disorder in the Early Period of Ischemic Stroke and Its Treatment with Ampakines

  • 期刊论文

  • 发表日期：

    2026年7月27日

查看全文
  • A. L. Khokhlov,
  • E. G. Lileeva,
  • Yu.V. Rybachkova,
  • Ch.A. Petrova,
  • E. F. Oko,
  • O. Yu. Arseenkova,
  • A. V. Kiselev

摘要

Objectives. To study the efficacy of ampakines (Ampasse) in patients with anxiety and depressive disorders in the early recovery period of ischemic stroke (IS). Materials and methods. The study included 203 patients in the early recovery period of IS, who underwent rehabilitation measures at the Doctor clinic (Tuymazy) from January 2023 to August 2025. The study included patients with IS occurring no later than three months before the start of the study, with signs of anxiety and depression not exceeding 10 points on the Hospital Anxiety and Depression Scale (HADS). Patients of the study group (SG, n = 102, age 63.2 ± 8.9 years, 48 women and 54 men) received Ampasse for 15 days along with standard therapy. Patients in the reference group (RG, n = 101, age 66.3 ± 8.1 years, 45 women and 56 men) received only basal therapy. The Beck Anxiety Inventory, Beck Depression Inventory, HADS, and Spielberger–Hanin Anxiety Inventory were used to assess psychoemotional state. Results. Improvements on all psychometric scales in the SG was statistically significantly greater than those in the RG. Conclusions. The study results showed that Ampasse had positive effects in terms of reducing the symptoms of anxiety and depression in patients in the early recovery period of ischemic stroke.